Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update

• Published in: International journal of pharmaceutics 2022-08, Vol.624, p.122022-122022, Article 122022
• Main Authors: Sainaga Jyothi, Vaskuri G.S., Bulusu, Raviteja, Venkata Krishna Rao, Balaga, Pranothi, Mulinti, Banda, Srikanth, Kumar Bolla, Pradeep, Kommineni, Nagavendra
• Format: Article
• Language: English
• Subjects: Characterization; Drug delivery; Liposomes; Stability; Sterilization
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2022.122022

[Display omitted] Liposomes have several advantages, such as the ability to be employed as a carrier/vehicle for a variety of drug molecules and at the same time they are safe and biodegradable. In the recent times, compared to other delivery systems, liposomes have been one of the most well-established and commercializing drug products of new drug delivery methods for majority of therapeutic applications. On the other hand, it has several limitations, particularly in terms of stability, which impedes product development and performance. In this review, we reviewed all the potential instabilities (physical, chemical, and biological) that a formulation development scientist confronts throughout the development of liposomal formulations as along with the ways to overcome these challenges. We have also discussed the effect of microbiological contamination on liposomal formulations with a focus on the use of sterilization methods used to improve the stability. Finally, we have reviewed quality control techniques and regulatory considerations recommended by the agencies (USFDA and MHLW) for liposome drug product development.